Pancragen
$74.99
Out of stock
Pancragen is a synthetic tetrapeptide bioregulator (CAS No. 8057‑49‑6) developed at the St. Petersburg Institute of Bioregulation and Gerontology under the leadership of Prof. Vladimir Khavinson. Designed as a peptide complex to target pancreatic tissues, Pancragen supports the structural and functional integrity of both the endocrine (islet) and exocrine (acinar) compartments of the pancreas. It is intended for in vitro and ex vivo research, especially in studies involving metabolic regulation, cell differentiation, and age-related pancreatic decline.
What is Pancragen Bioregulator Pancragen?
Pancragen is a synthetic tetrapeptide bioregulator (CAS No. 8057‑49‑6) developed at the St. Petersburg Institute of Bioregulation and Gerontology under the leadership of Prof. Vladimir Khavinson. Designed as a peptide complex to target pancreatic tissues, Pancragen supports the structural and functional integrity of both the endocrine (islet) and exocrine (acinar) compartments of the pancreas. It is intended for in vitro and ex vivo research, especially in studies involving metabolic regulation, cell differentiation, and age-related pancreatic decline.
Amino Acid Sequence and Chemical Properties
- Sequence: Lysine – Glutamic acid – Aspartic acid – Tryptophan (KEDW)
- Molecular Formula: C₂₆H₃₆N₆O₉
- Molecular Weight: 576.25 Da
- CAS Number: 8057-49-6
- PubChem CID: 68452887
- Structure: Linear tetrapeptide, no post-translational or terminal modifications
Mechanism of Action
Pancragen is believed to work through the following cellular mechanisms:
- Gene Regulation: Penetrates the nucleus to modulate gene transcription, especially genes involved in pancreatic differentiation (e.g., Pdx1, Pax6, Foxa2, Pax4, Nkx2.2).
- Epigenetic Reprogramming: Promotes DNA demethylation and histone remodeling at key loci associated with insulin production and cell survival.
- Anti-apoptotic Activity: Downregulates caspase-3, p53, and cathepsin B expression while upregulating Mcl1 and PCNA, thereby enhancing cell viability.
- Cellular Proliferation: Increases Ki67, MMP2, and MMP9—markers of regeneration and tissue remodeling.
- Vascular Support: Improves microvascular function in pancreatic tissues, with potential protection against capillary fragility and ischemic stress.
Purported Benefits (Research-Based Observations)
Although Pancragen is not approved for therapeutic use, it has been widely studied in animal and limited human contexts, particularly within the Russian scientific literature. Purported benefits based on these studies include:
- Improved Glucose Metabolism: Normalization of blood glucose, insulin, and C-peptide levels in aged animal models.
- Pancreatic Regeneration: Restoration of aged or damaged pancreatic islet and acinar cells through cellular reprogramming and enhanced regeneration.
- Anti-Diabetic Potential: Positive modulation of insulin-producing beta cells and glucagon-secreting alpha cells.
- Protection from Age-Related Decline: Restoration of gene expression profiles linked to youthful pancreatic function.
- Enhanced Enzyme Secretion: Improved exocrine pancreatic enzyme activity supporting digestion and metabolic efficiency.
These effects are believed to result from Pancragen’s influence on cellular programming, not from pharmacologic suppression or hormone replacement.
In Vitro Research Applications
Pancragen is suitable for research into:
- Endocrine regulation and islet cell differentiation
- Fibrosis and remodeling in pancreatic tissue
- Epigenetic gene regulation in senescent cells
- Microvascular health under diabetic or oxidative stress conditions
- Stem cell–based models of pancreatic regeneration
Specifications
| Feature | Detail |
| Name | Khavinson Bioregulator Pancragen |
| Amino Acid Sequence | Lys–Glu–Asp–Trp (KEDW) |
| CAS Number | 8057-49-6 |
| Molecular Weight | 576.25 Da |
| Form | Lyophilized peptide powder (10 mg, 20 mg vials) |
| Purity | ≥95% (HPLC-grade) |
| Storage | -20 °C (dry); 2–8 °C post-reconstitution |
| Intended Use | For research use only in laboratory studies |
Future Research Opportunities
- Organoid and co-culture studies to mimic in vivo pancreatic microenvironments.
- CRISPR- and RNAseq-based assays to assess gene activation profiles following peptide exposure.
- In vitro diabetes models for beta-cell recovery and insulin expression analysis.
- Methylome mapping to track changes in epigenetic age markers under peptide influence.
References
- PeptideSciences. “Pancragen Bioregulator.”
- NovoPro Peptides. “Tetrapeptide KEDW Specifications and Research Applications.”
- Khavinson V. et al., ResearchGate/PMC articles on differentiation gene upregulation and anti-apoptotic effects.
- Limitless Life Nootropics. “Pancragen—Peptide for Pancreatic Support.”
- Korkushko O.V. et al., “Impact of Pancragen on pancreatic cell proliferation and gene expression.”
Disclaimer
This product is intended for research purposes only. It is not approved for human or veterinary use, nor is it intended for clinical, diagnostic, or therapeutic applications. All research must comply with applicable local laws and institutional guidelines. Misuse of this compound for human consumption is strictly prohibited.